Grant: Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
University of British Columbia
$20,000.00
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
FY 2022-23
Summary
A process called immune tolerance allows the immune system to fend off dangerous foreign substances yet leave the body's own tissues untouched. When immune tolerance fails, the resulting chronic inflammation can lead to many different diseases including cardiovascular and autoimmune diseases as well as transplant rejection. As there are no medications that promote immune tolerance, patients are on long-term immune suppressants that are not curative and have toxic side-effects. Our goal is to move beyond symptom management for inflammatory disease and find safe, long-term solutions. We have been working towards this goal by developing a therapy that takes advantage of a specialized type of white blood cell, called regulatory T cells, or Tregs, which suppress undesired immune responses, promote tissue healing and help re-establish a balanced immune system. Tregs are extremely rare in circulating blood, but we have shown that an organ called the thymus (which is routinely removed and discarded during heart surgery) is an abundant source of easily-isolated and pure Tregs. This allowed us to develop methods for producing large numbers of Tregs from the thymus for clinical use. We also showed that thymus Tregs improve immune tolerance in mouse models of transplantation. We now aim to conduct a clinical trial to determine if thymus Tregs are a safe and effective way to prevent chronic inflammation after bone marrow (immune system) transplantation, when the donor immune system has the potential to attack healthy tissue in the recipient. We have partnered with a cross-Canada team of clinicians, national medical networks and people with lived experience to design and conduct this clinical trial. Once we establish safety and effectiveness of thymic Tregs in the context of transplantation, we will be able to extend testing of "off-the-shelf" Treg therapy to many other inflammatory diseases.
Department
Program
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
485529
Name
Levings Megan K
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Team Grant : Intervention Trial in Inflammation for Chronic Conditions
Projecttitle
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Keyworddelim
Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
Abstract
A process called immune tolerance allows the immune system to fend off dangerous foreign substances yet leave the body's own tissues untouched. When immune tolerance fails, the resulting chronic inflammation can lead to many different diseases including cardiovascular and autoimmune diseases as well as transplant rejection. As there are no medications that promote immune tolerance, patients are on long-term immune suppressants that are not curative and have toxic side-effects. Our goal is to move beyond symptom management for inflammatory disease and find safe, long-term solutions. We have been working towards this goal by developing a therapy that takes advantage of a specialized type of white blood cell, called regulatory T cells, or Tregs, which suppress undesired immune responses, promote tissue healing and help re-establish a balanced immune system. Tregs are extremely rare in circulating blood, but we have shown that an organ called the thymus (which is routinely removed and discarded during heart surgery) is an abundant source of easily-isolated and pure Tregs. This allowed us to develop methods for producing large numbers of Tregs from the thymus for clinical use. We also showed that thymus Tregs improve immune tolerance in mouse models of transplantation. We now aim to conduct a clinical trial to determine if thymus Tregs are a safe and effective way to prevent chronic inflammation after bone marrow (immune system) transplantation, when the donor immune system has the potential to attack healthy tissue in the recipient. We have partnered with a cross-Canada team of clinicians, national medical networks and people with lived experience to design and conduct this clinical trial. Once we establish safety and effectiveness of thymic Tregs in the context of transplantation, we will be able to extend testing of "off-the-shelf" Treg therapy to many other inflammatory diseases.
Competitiondate
202303
Approvedterm2
1 yr 0 mth
Pinamesdelim
Levings, Megan K; Delisle, Jean-Sébastien; Ahmad, Imran; Dijke, Ilona E; Elsawy, Mahmoud E; Hay, Kevin A; Kekre, Natasha; Szwajcer, David; West, Lori J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $20,000~ $0~